XOMA to Present at the Cowen and Company 39th Annual Health Care Conference
March 05 2019 - 07:00AM
XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive
Officer, Jim Neal, will present an update about the company’s
business at the Cowen and Company 39th Annual Health Care
Conference in Boston, Massachusetts. The presentation will
take place on Tuesday, March 12, 2019, at 12:00PM ET, and can be
accessed via a live webcast on the investor relations page of
XOMA’s website at www.xoma.com. An archived version of the
webcast will be available for 90 days after the event.
About XOMA CorporationXOMA has built a
significant portfolio of products that are licensed to and being
developed by other biotechnology and pharmaceutical companies.
The Company’s portfolio of partner-funded programs spans
multiple stages of the drug development process and across various
therapeutic areas. Many of these licenses are the result of
XOMA’s pioneering efforts in the discovery and development of
antibody therapeutics. The Company’s royalty-aggregator
business model includes acquiring additional licenses to
partner-funded programs. XOMA’s license portfolio has the
potential to generate significant milestone payments and royalty
revenue in the future. For more information, visit
www.xoma.com.
Forward-Looking Statements/Explanatory
NotesCertain statements contained in this press release
are forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including statements regarding the potential
of XOMA’s portfolio of partnered programs and licensed technologies
generating substantial milestone and royalty proceeds over time.
These statements are based on assumptions that may not prove
accurate, and actual results could differ materially from those
anticipated due to certain risks inherent in the biotechnology
industry, including those related to the fact that our product
candidates subject to out-license agreements are still being
developed, and our licensees may require substantial funds to
continue development which may not be available; we do not know
whether there will be, or will continue to be, a viable market for
the products in which we have an ownership or royalty interest; we
may not be successful in entering into out-license agreements for
our product candidates; if our therapeutic product candidates do
not receive regulatory approval, our third-party licensees will not
be able to manufacture and market them. Other potential risks
to XOMA meeting these expectations are described in more detail in
XOMA's most recent filing on Form 10-K and in other SEC filings.
Consider such risks carefully when considering XOMA's
prospects. Any forward-looking statement in this press
release represents XOMA's views only as of the date of this press
release and should not be relied upon as representing its views as
of any subsequent date. XOMA disclaims any obligation to
update any forward-looking statement, except as required by
applicable law.
EXPLANATORY NOTE: All references to “portfolio” in this press
release are to milestone and/or royalty rights associated with drug
products in development. All references to “assets” in this
presentation are to milestone and/or royalty rights associated with
individual drug products in development.
Investor contact:Juliane
SnowdenOratorium Group, LLC+1
646-438-9754jsnowden@oratoriumgroup.com
Media contact:Kathy VincentKV
Consulting & Management+1
310-403-8951kathy@kathyvincent.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Feb 2024 to Mar 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2023 to Mar 2024